Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials

References

• World Health Organization. WHO COVID-19 dashboard. World Health Organization; 2022. Available from: https://covid.19.who.int/data. Accessed October 11, 2023.
   Google Scholar
• Shao W, Chen X, Zheng C, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. Emerg Microbes Infect. 2022;11(1):2383–2392. doi:10.1080/22221751.2022.2122582
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753–758. doi:10.1136/postgradmedj-2020-138234
   PubMed Web of Science ®Google Scholar
• Meselson M. Droplets and Aerosols in the Transmission of SARS-CoV-2. N Engl J Med. 2020;382(21):2063. doi:10.1056/NEJMc2009324
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–284. doi:10.1038/s41579-022-00713-0
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu J, Wang H, et al. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. Cell. 2020;182(2):417–428.e13. doi:10.1016/j.cell.2020.05.034
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Monice M, Mehboob S, Jones CL, Lawrence S. Post-acute (long) COVID-19 quality of life: validation of the German version of (PAC19QoL) instrument. Front Public Health. 2023;11:1163360. doi:10.3389/fpubh.2023.1163360
   PubMed Web of Science ®Google Scholar
• Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019
   PubMedGoogle Scholar
• Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427. doi:10.1136/bmjgh-2021-005427
   PubMed Web of Science ®Google Scholar
• Chanda D, Hines JZ, Itoh M, Fwoloshi S, Minchella PA, Zyambo KD. COVID-19 vaccine effectiveness against progression to in-hospital mortality in Zambia, 2021–2022. Open Forum Infect Dis. 2022;9(9):ofac469. doi:10.1093/ofid/ofac469
   PubMed Web of Science ®Google Scholar
• National health commission of the people’s republic of China. Available from: https://www.nhc.gov.cn/xcs/yqjzqk/202212/a87d93dbfbd14fc1b7837f1a20092cbe.sht.mL. Accessed October 11, 2023.
   Google Scholar
• Hong J, Xu XW, Yang J, et al. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: a cross-sectional survey. J Integr Med. 2022;20(1):34–44. doi:10.1016/j.joim.2021.10.004
   PubMedGoogle Scholar
• Majeed A, Molokhia M. Vaccinating the UK against covid-19. BMJ. 2020;371:m4654. doi:10.1136/bmj.m4654
   PubMed Web of Science ®Google Scholar
• World Health Organization. Ten Threats to Global Health in 2019; 2019. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed October 11, 2023.
   Google Scholar
• Umakanthan S, Lawrence S. Predictors of COVID-19 vaccine hesitancy in Germany: a cross-sectional, population-based study. Postgrad Med J. 2022;98(1164):756–764. doi:10.1136/postgradmedj-2021-141365
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Bukelo MM, Bukelo MJ, Patil S, Subramaniam N, Sharma R. Social environmental predictors of COVID-19 vaccine hesitancy in India: a population-based survey. Vaccines. 2022;10(10):1749. doi:10.3390/vaccines10101749
   Web of Science ®Google Scholar
• Christie A, Mbaeyi SA, Walensky RP. CDC interim recommendations for fully vaccinated people: an important first step. JAMA. 2021;325(15):1501–1502. doi:10.1001/jama.2021.4367
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Management. COVID-19 Treatment Guidelines. Available from: https://www.covid19.treatment.guidelines.nih.gov/ma-nagement/. Accessed October 11, 2023.
   Google Scholar
• Kumari M, Lu RM, Li MC, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci. 2022;29(1):68. doi:10.1186/s12929-022-00852-9
   PubMed Web of Science ®Google Scholar
• Ferner RE, Aronson JK. Remdesivir in covid-19. BMJ. 2020;369:m1610. doi:10.1136/bmj.m1610
   PubMedGoogle Scholar
• Drożdżal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat. 2021;59:100794. doi:10.1016/j.drup.2021.100794
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Inter J Surg. 2021;88:105906. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Xu C, Niu Y, Wu J, Gu H, Zhang C. Software and package applicating for network meta-analysis: a usage-based comparative study. J Evid Based Med. 2018;11(3):176–183. doi:10.1111/jebm.12264
   PubMedGoogle Scholar
• Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017;39:e2017047. doi:10.4178/epih.e2017047
   PubMed Web of Science ®Google Scholar
• Béliveau A, Boyne DJ, Slater J, Brenner D, Arora P. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol. 2019;19(1):196. doi:10.1186/s12874-019-0829-2
   PubMed Web of Science ®Google Scholar
• Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi:10.1186/1471-2288-14-135
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG. Assessing risk of bias in included studies. Cochrane Handbook Syst Rev Inter. 2011;2011:187–241.
   Google Scholar
• Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409–6416. doi:10.1172/JCI141772
   PubMed Web of Science ®Google Scholar
• Cherian JJ, Eerike M, Bagepally BS, Das S, Panda S. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: a comparison using systematic review and meta-analysis. Front Pharmacol. 2022;13:1004308. doi:10.3389/fphar.2022.1004308
   PubMed Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi:10.1186/s13075-019-1964-1
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. doi:10.1016/S0140-6736(20)30304-4
   PubMed Web of Science ®Google Scholar
• Hoang TN, Pino M, Boddapati AK, et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell. 2021;184(2):460–475.e21. doi:10.1016/j.cell.2020.11.007
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. U.S. Food and drug administration; 2022. Available from: https://www.fda.gov/media/143822/download. Accessed October 11, 2023.
   Google Scholar
• RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400(10349):359–368. doi:10.1016/S0140-6736(22)01109-6
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo- controlled Phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418. doi:10.1016/S2213-2600(21)00331-3
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356. doi:10.1016/j.jinf.2020.04.017
   PubMed Web of Science ®Google Scholar
• Awad H, Hassan B, Dweek S, Aboelata Y, Rawas-Qalaji M, Ahmed IS. Repurposing potential of the antiparasitic agent ivermectin for the treatment and/or prophylaxis of COVID-19. Pharmaceuticals. 2022;15(9):1068. doi:10.3390/ph15091068
   Web of Science ®Google Scholar
• Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, Pena L. Ivermectin: an award-winning drug with expected antiviral activity against COVID- 19. J Control Release. 2021;329:758–761. doi:10.1016/j.jconrel.2020.10.009
   PubMed Web of Science ®Google Scholar
• Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. EClinicalMedicine. 2021;37:100959. doi:10.1016/j.eclinm.2021.100959
   PubMedGoogle Scholar
• Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? J Travel Med. 2021;28(2):taab005. doi:10.1093/jtm/taab005
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.104787
   PubMed Web of Science ®Google Scholar
• Okumuş N, Demirtürk N, Çetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21(1):411. doi:10.1186/s12879-021-06104-9
   PubMed Web of Science ®Google Scholar
• Jean SS, Hsueh PR. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther. 2020;18(9):843–847. doi:10.1080/14787210.2020.1771181
   PubMed Web of Science ®Google Scholar
• López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):142 6–1435. doi:10.1001/jama.2021.3071
   Google Scholar
• Hung DT, Ghula S, Aziz JMA, et al. The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis. 2022;120:217–227. doi:10.1016/j.ijid.2022.04.035
   PubMed Web of Science ®Google Scholar
• Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64(12):e01897–20. doi:10.1128/AAC.01897-20
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454. doi:10.1016/j.antiviral.2013.09.015
   PubMed Web of Science ®Google Scholar
• Vashchenko I, A. A, Dmitriev KA, et al. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a Phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021;73(3):531–534. doi:10.1093/cid/ciaa1176
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Mösbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020;585(7826):588–590. doi:10.1038/s41586-020-2575-3
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and resistance in India explored through a population-based longitudinal survey. Vaccines. 2021;9(10):1064. doi:10.3390/vaccines9101064
   Web of Science ®Google Scholar